Dermira Inc. (NASDAQ:DERM) traded down 2.5% during trading on Monday . The stock traded as low as $31.39 and last traded at $31.44, with a volume of 61,718 shares trading hands. The stock had previously closed at $32.26.

Several equities research analysts recently commented on the company. Zacks Investment Research downgraded Dermira from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Wedbush raised their target price on Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 2nd. Needham & Company LLC raised their target price on Dermira from $42.00 to $46.00 and gave the company a “buy” rating in a report on Thursday, June 2nd. Finally, Leerink Swann reiterated a “buy” rating and set a $47.00 target price (up from $46.00) on shares of Dermira in a report on Thursday, June 2nd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $40.83.

The firm’s market cap is $941.36 million. The stock has a 50 day moving average of $30.88 and a 200-day moving average of $26.77.

Dermira (NASDAQ:DERM) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.01. Analysts anticipate that Dermira Inc. will post ($3.51) earnings per share for the current fiscal year.

In other Dermira news, CEO Thomas G. Wiggans sold 11,000 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $33.19, for a total value of $365,090.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Luis C. Pena sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 15th. The shares were sold at an average price of $29.47, for a total value of $294,700.00. Following the completion of the transaction, the insider now owns 7,653 shares in the company, valued at approximately $225,533.91. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Morgan Stanley increased its stake in Dermira by 82.2% in the fourth quarter. Morgan Stanley now owns 42,767 shares of the biopharmaceutical company’s stock valued at $1,480,000 after buying an additional 19,299 shares during the period. Jennison Associates increased its stake in Dermira by 98.7% in the third quarter. Jennison Associates now owns 1,013,343 shares of the biopharmaceutical company’s stock valued at $23,651,000 after buying an additional 503,237 shares during the period. Finally, Jennison Associates LLC increased its stake in Dermira by 8.3% in the fourth quarter. Jennison Associates LLC now owns 1,097,201 shares of the biopharmaceutical company’s stock valued at $37,974,000 after buying an additional 83,858 shares during the period.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.